Peripheral Nerve Repair
5% Dextrose Hydrodissection × PRP × Continuous Ultrasound GuidanceCarpal · cubital · sciatic · post-op nerve adhesion | Taiwan research developed over years: Wu YT 2017 Mayo Clin Proc
Taiwan Research Focus · Seeing Nerves · Honest Triage
Taiwan Research Teams With Years of Focus
CTS 5% dextrose nerve hydrodissection is a research area Taiwan has focused on for years — Tri-Service General Hospital Wu YT group 2017 Mayo Clin Proc (PMID:28734327) is a landmark RCT; Lin CP 2020 NMA (PMID:32197544) ranks D5W #1 by BCTQ-SSS. We stand on the shoulders of Taiwan's research.
Ultrasound-Guided "See the Nerve"
Perineural hydrodissection cannot afford "hitting the nerve itself" or "hitting a vessel." We use continuous US guidance — needle tip, nerve, and vessels all simultaneously visible. Accuracy rises from 50-80% (blind) to 95%+. Lin 2024 umbrella review (PMID:39219174) confirms US guidance consistently outperforms landmark.
No Pushing D5W to Delay Necessary Surgery
For mild-to-moderate CTS we strongly recommend D5W hydrodissection — the strongest evidence option. But for severe CTS (visible thenar atrophy, absent SNAP, DML > 8 ms), AAOS 2024 guideline clearly recommends direct surgery — we honestly tell you and refer to hand surgery. A responsible physician does not say "let's try D5W first" just to bill another session.
Liusmed Clinic — Cross-Specialty Core Principles
From skin tumors to peripheral nerves, "you can only treat what you can see" is our unwavering creed. Perineural hydrodissection cannot afford "hitting the nerve itself" — ultrasound makes needle tip, nerve, and vessels simultaneously visible, the respect a nerve deserves.
You Might Be Experiencing
The traditional path for peripheral neuropathy was "rest → brace → steroids → surgery." Repeated steroid injections can damage perineural tissue; surgery carries risk. Regenerative medicine offers a fourth path: 5 mL of 5% dextrose injected via fine needle along the epineurium to physically separate adhesions and deliver repair signals.
- Hand numb wakes you at night, shaking helps (classic CTS)
- Numbness in little and ring fingers (cubital tunnel syndrome)
- Tingling on wrist motion, grip weakness
- Buttock-to-posterior-thigh pain after sitting (piriformis/sciatica)
- Numbness returned post-surgery — thinking "another surgery" is the only answer
- Steroid tried but effect not lasting
Why Can 5 mL of Dextrose Improve Symptoms for 6+ Months?
When a nerve is compressed or adhered, it becomes ischemic, conducts slowly, and produces numbness and pain. "Nerve hydrodissection" uses fluid itself for physical separation, combined with 5% dextrose's special mechanism, achieving repair without steroid or tissue damage.
Hydrodissection: Physical Adhesion Separation
When a nerve is compressed or adhered to surrounding tendons, ligaments, or connective tissue, it becomes ischemic, conducts slowly, and produces numbness and pain. "Nerve hydrodissection" uses 5 mL of 5% dextrose injected via fine needle along the epineurium — **the fluid itself acts like "unzipping" to physically separate nerve from adhesion** — pure mechanical release, not drug or steroid.
5% Dextrose: Cumulative Repair, Non-Damaging
The 5% dextrose advantage is precisely "non-suppression" — unlike steroid, it does not depress perineural tissue causing long-term atrophy. It gently stimulates local TRPV1 receptors (pain modulation) and improves perineural nourishment. Wu 2018 RCT shows D5W superior to steroid at 4-6 months. "Better with more rounds" is D5W's nature — not true of steroid.
PRP: Advanced Option for Severe Cases
PRP (platelet-rich plasma) contains PDGF (Platelet-Derived Growth Factor), VEGF (Vascular Endothelial Growth Factor), IGF-1 (Insulin-like Growth Factor 1) growth factors providing direct repair signaling to perineural tissue. Wu 2017 Sci Rep RCT shows PRP outperforms control over 6 months for CTS; Shen 2019 RCT: PRP slightly superior to D5W on BCTQ-FSS and DML. But AAOS 2024 guideline states "strong evidence shows PRP does not provide long-term benefit for CTS" — so we position PRP as a "stronger mid-term (3-6 months) effect" option; long-term management requires patient preparation.
What the Studies Say — What It Means for You
We surface the 4 most pivotal studies on "nerve hydrodissection" — 3 of them from Taiwan. Each has "what it means for you" translating academic numbers into clinic-room questions.
D5W Hydrodissection vs PRP vs Steroid vs Surgery
| Item | D5W Hydrodissection (Our First Choice) | PRP | Steroid | Surgery |
|---|---|---|---|---|
| Mechanism | Physical adhesion separation + perineural nourishment + analgesia | Growth factors directly repair perineural tissue | Suppress inflammation, analgesia | Physically release transverse carpal ligament etc. |
| Evidence (CTS) | ★★★★ (NMA SMD #1, Wu 2017/2018 RCT) | ★★★ NMA (Network Meta-Analysis) #2; AAOS does not support long-term | ★★ short-term (≤3 mo, Cochrane 2023); not supported long-term | ★★★★ first-line for severe (AAOS 2024 strong) |
| Side Effects / Risks | Brief site distension < 24h, rare intraneural < 1% | 24-72h pain, bruising; 20-40% limited improvement | Repeat use atrophies perineural tissue, depigmentation (blind 11% vs US 3%) | Anesthesia, infection, nerve injury, recurrence (5-10%) |
| Repeatability | Repeatable (better with more) | Repeatable | Cochrane: 2nd injection no extra benefit | One-time (re-op risky) |
| Our Position | First-line for mild-moderate CTS/UNE; post-op recurrent | Stronger mid-term option (with AAOS dissent disclosed) | Short-term bridging for acute flare | Refer for severe CTS (thenar atrophy) |
Key Insight: D5W hydrodissection is not "cheaper steroid" — it is "a different category of therapy mechanistically better suited to long-term management." The best path for most patients: try D5W first (NMA #1) → add PRP if mid-term unsatisfactory → surgery only for severe. We will not push D5W to delay necessary surgery just to bill another session.
Why Liusmed Clinic Chose "D5W × Ultrasound Guidance"
We do not pitch a single magic bullet. Literature has long told us D5W nerve hydrodissection is the most effective non-surgical option for CTS, with ultrasound guidance making it safer. Two axes behind our choice:
Literature Support
- ·Wu YT 2017 Mayo Clin Proc (PMID:28734327): single 5 mL D5W significantly improves BCTQ-SSS, CSA, DML at 6 months (large effect). Taiwan Tri-Service Hospital has focused on this therapy over years.
- ·Wu YT 2018 Ann Neurol (PMID:30187524): D5W vs triamcinolone double-blind RCT, D5W superior to steroid at 4-6 months.
- ·Lin CP 2020 NMA (PMID:32197544): D5W ranked #1 by SMD on BCTQ-SSS and FSS; PRP #2; steroid #3.
- ·Chen LC 2020 RCT (PMID:32325164): UNE 6-month double-blind RCT, D5W superior to steroid from month 3 on symptom severity and nerve CSA reduction (p<0.05).
- ·Chao 2022 (PMID:35806998): post-op recurrent CTS D5W — mean 3.1 injections, 61.1% effective; "true recurrent" excellent outcome 61.6%.
Dr. Liu — Clinical Observations
- ·Ultrasound guidance lets us "see the nerve" — non-negotiable safety prerequisite for perineural hydrodissection. Needle tip, nerve, and vessels visible throughout, avoiding the worst complication: intraneural injection. "You can only treat what you can see" is Liusmed Clinic's cross-specialty creed.
- ·Many patients have "tried steroid a few times without lasting effect" — this is exactly what Cochrane 2023 wrote: "short-term effective, long-term ineffective." We will not keep pushing steroid; we tell you directly: D5W is a different therapy, different mechanism, different long-term outcome.
- ·For severe CTS (thenar atrophy, absent SNAP), AAOS 2024 clearly recommends direct surgery. We honestly say: "D5W may be too late at your severity; we recommend hand-surgery evaluation first; come back for post-op maintenance if needed." A responsible physician does not push patients to use D5W to delay necessary surgery.
- ·CTS post-op recurrence is a common "gray zone" — re-operation is risky and many patients are stuck. Chao 2022 gave us evidence-based answer: D5W mean 3.1 injections, 61.1% reach "effective" (≥50% improvement). Post-op recurrence does not always need re-surgery.
- ·We track via BCTQ-SSS, BCTQ-FSS, grip strength, ultrasound CSA at 2 wk / 1 mo / 3 mo / 6 mo. Objective numbers beat subjective feel — and this is what patients end up valuing most.
We did not pick the "newest, flashiest" — we picked the combination with the strongest current evidence, alignment with our cross-specialty philosophy, and the highest chance you can avoid (re-)surgery.
Treatment Process
From evaluation to follow-up, five stages ensuring precise triage and lasting effect
Clinic Evaluation
BCTQ + Tinel/Phalen + history
Ultrasound + NCS if needed
Nerve CSA, severity grading
Individualized Injectate Selection
D5W first; PRP advanced; severe → surgery
US-Guided Hydrodissection
Needle/nerve/vessel visible throughout
BCTQ/Grip Strength Follow-Up
2 wk / 1 mo / 3 mo / 6 mo
Clinical Evidence & References
5% dextrose nerve hydrodissection is "off-label." Taiwan research teams (Wu YT, Lin MT, Chang KV) have developed this therapy over years with abundant peer-reviewed evidence. PRP for perineural hydrodissection is performed under Special Medical Technology Regulations; AAOS 2024 does not support long-term benefit. We explicitly disclose off-label status in informed consent and track each patient objectively via BCTQ, grip strength, and ultrasound CSA.
- [1]OCEBM 1b2017
Wu YT, et al.. Six-Month Efficacy of Perineural Dextrose for Carpal Tunnel Syndrome: A Prospective, Randomized, Double-Blind, Controlled Trial. Mayo Clin Proc 92(8):1179-1189.
Landmark RCT (Randomized Controlled Trial): D5W vs saline double-blind, single 5 mL injection significantly improves BCTQ-SSS, FSS, VAS (Visual Analog Scale), median nerve CSA, DML at 6 months (large effect). A research area Taiwan has focused on for years.
PMID: 28734327 - [2]OCEBM 1b2018
Wu YT, et al.. Six-month efficacy of perineural dextrose injection vs corticosteroid in carpal tunnel syndrome: A double-blind, randomized controlled trial. Ann Neurol 84(4):601-610.
D5W vs triamcinolone double-blind RCT: single injection followed for 6 months — D5W outperformed steroid at 4-6 months on BCTQ-SSS, nerve CSA, DML (p<0.05).
PMID: 30187524 - [3]OCEBM 1a2020
Lin CP, et al.. A Comparative Effectiveness of Different Injectates in Carpal Tunnel Syndrome: A Systematic Review and Network Meta-Analysis. Pharmaceuticals (Basel) 13(3):49.
Injectate network meta-analysis: D5W ranked #1 by SMD (Standardized Mean Difference) on BCTQ-SSS (symptom severity) and FSS (function); PRP #2; steroid #3.
PMID: 32197544 - [4]OCEBM 1b2020
Chen LC, et al.. Ultrasound-Guided 5% Dextrose Hydrodissection Versus Steroid Injection in Cubital Tunnel Syndrome: A Randomized Controlled Trial. Arch Phys Med Rehabil 101(8):1296-1303.
Cubital tunnel syndrome 6-month double-blind RCT (n=33): single-injection D5W vs triamcinolone — both effective; from month 3, D5W showed significantly greater symptom severity and nerve CSA reduction (p<0.05).
PMID: 32325164 - [5]OCEBM 2b2022
Chao TC, et al.. Ultrasound-Guided Perineural Injection with 5% Dextrose for Recurrent or Persistent Carpal Tunnel Syndrome After Surgery: A Retrospective Clinical Study. J Clin Med 11(13):3705.
Post-op recurrent/residual CTS D5W retrospective (n=36): mean 3.1 injections, mean 33-month follow-up; 61.1% reached "effective" (≥50% improvement); "true recurrent" excellent outcome 61.6% vs "persistent" 13% (p=0.006).
PMID: 35806998 - [6]OCEBM 1a2023
Ashworth NL, et al.. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst Rev 2:CD015148.
Cochrane SR (Systematic Review): corticosteroid vs placebo for CTS — short-term (≤3 months) significantly effective (high-quality evidence); long-term (>3 months) insufficient or no benefit.
PMID: 36722795 - [7]OCEBM G2024
Shapiro LM, Kamal R, et al.. AAOS Clinical Practice Guideline: Management of Carpal Tunnel Syndrome. J Am Acad Orthop Surg 33(7):e356-e366.
AAOS 2024 CPG: Strong evidence shows PRP injection (LR or LP) does not provide long-term benefit for CTS (rated equivalent to steroid as "no long-term benefit"). Severe CTS still warrants surgery.
PMID: 39637428 - [8]OCEBM 1b2017
Maniquis-Smigel L, Reeves KD, et al.. Short Term Analgesic Effects of 5% Dextrose Epidural Injections for Chronic Low Back Pain. Anesth Pain Med 6(1):e42550.
32 chronic LBP with sciatica RCT: 10 mL D5W vs saline single caudal epidural; at 4h, 84% vs 19% achieved ≥50% pain reduction (p<0.001), still significant at 2 weeks (p=0.012).
Our Commitment to Honest Disclosure
Every procedure deserves your full understanding before deciding. The following summarizes common considerations and current research context; individual applicability is evaluated by the physician so you can proceed with confidence.
Contraindications
- •Active injection-site infection, severe coagulopathy
- •Complete nerve transection, cauda equina, progressive nerve deficit (surgical emergency)
- •Severe CTS (thenar atrophy, absent SNAP) — direct surgery recommended
- •Active malignancy, pregnancy (relative), injectate component allergy
Common Side Effects
- •D5W: transient site distension < 24h, occasional brief numbness flare < 1 week
- •PRP: 24-72h post-injection pain, bruising; 20-40% have limited improvement
- •Rare intraneural injection, bleeding, infection (< 1%; US guidance markedly reduces risk)
- •Diabetic patients: 5 mL 5% D5W contains 0.25 g glucose, minimal impact; still advise informing primary physician
Research Status & Clinical Observations
- •5% dextrose nerve hydrodissection is "off-label": labeled use is IV infusion; abundant peer-reviewed evidence supports its use (Wu 2017 Mayo Clin Proc, Lin CP 2020 NMA, Pan 2023 NMA), but off-label status must be explicitly disclosed in informed consent.
- •AAOS dissenting view on PRP long-term benefit for CTS: AAOS 2024 CPG states "strong evidence shows PRP does not provide long-term benefit for CTS," equivalent to steroid as "no long-term benefit." We honestly explain this guideline position and position PRP as "stronger mid-term (3-6 months) effect."
- •Honest disclosure of evidence-level stratification: D5W for CTS/UNE is Level I (multiple RCTs + meta-analyses); post-op recurrent CTS is Level II (Chao 2022 retrospective); caudal epidural D5W for sciatica is Level I-II; piriformis/deep gluteal US-guided perisciatic hydrodissection is Level III (case series). We tell you the evidence level for your location — no overclaiming.
Transparent Pricing Ranges
| Item | Price Range | Notes |
|---|---|---|
| Initial evaluation (BCTQ + US + NCS/EMG if needed) | Quoted per case | — |
| US-guided D5W nerve hydrodissection (single) | Quoted per case | Varies slightly by nerve site, dose, follow-up frequency |
| PRP perineural injection (advanced, stronger mid-term) | Quoted per case | Per Special Medical Technology Regulations; AAOS 2024 does not support long-term benefit — full disclosure required |
| Caudal epidural D5W (sciatica with LBP) | Quoted per case | Per case evaluation; rule out cauda equina |
Actual pricing depends on individual symptoms, treatment count, and custom formulation — explained on a case-by-case basis via LINE consultation or in-person visit. We value transparent pricing, with the physician walking you through your individual situation.
FAQ
5% Dextrose hydrodissection vs steroid — which is better?
Why this treatment in Taiwan? Does the Taiwan team have related research?
Can I avoid surgery for my carpal tunnel syndrome?
How soon will I feel improvement?
Is sciatica suitable?
I had the surgery, why is the numbness back?
Is 5% dextrose legal in Taiwan? Off-label?
Who should not have this treatment?
Dr. Ta-Ju Liu
Director, Liusmed Clinic · Over 15 years in minimally-invasive treatment
- Former attending dermatologist, Chang Gung Medical Center & Cosmetic Center
- Board-certified dermatologist · minimally-invasive surgery focus
- Advanced ultrasound-guided procedures · filler complication repair · complete apocrine gland clearance
"You can only treat what you can see" is the core belief running through every procedure I do. The subcutaneous world is intricate; what used to depend on experience and palpation now has a more reliable lens — advanced ultrasound. Seeing vessels, nerves, capsules, and glands first, then deciding where and how deep to cut — that is the standard every patient deserves.
Numbness Is Not Something to "Tough Out" — Let Us See the Nerve with Ultrasound First, Then Decide
We are not "injection machines." Every pre-injection evaluation, ultrasound localization, and conversation with you is designed so "you do not have to come back" or "you do not have to (re-)operate." Start with LINE consultation or book in-person.
"See the nerve" under ultrasound · 5% dextrose cumulative repair · no tissue damage
Wu 2017 / 2018 RCTs support D5W efficacy for CTS / ulnar entrapment · honest surgery referral when warranted
Your Nerve Repair Treatment Includes
Hydrodissection · physical separation of adhesions
Fluid cushion separates nerve from surrounding tissue · releases compression
5% dextrose · cumulative repair, non-damaging
Ultrasound-guided "see the nerve"
No pushing D5W to delay necessary surgery
When nerve conduction damage is severe, surgical referral is the honest call · D5W suits mild-to-moderate cases
※ Click any chip to view full scope and exclusion terms
Want to know which path fits your situation? Either way works — pick whichever feels easier.